Lenz Therapeutics, a San Diego, CA-based biopharmaceutical company with a lead late clinical-stage program that represents a potential therapy for presbyopia, raised $47m in Series A funding.
Backers included Versant Ventures and RA Capital Management.
The company intends to use the funds to progress its lead asset, an eyedrop formulation of aceclidine, towards an NDA submission for the treatment of presbyopia.
Led by Eef Schimmelpennink, CEO, Lenz Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Its lead program, aceclidine, is an eye drop designed to restore the loss of near vision associated with presbyopia. Aceclidine is an NCE in the U.S. and has an established safety profile from its prior use in Europe for glaucoma.
Board members include:
- Clare Ozawa, Ph.D., managing director at Versant; and
- Zach Scheiner, Ph.D., Principal at RA Capital Management.